Skip to content

Advertisement

Volume 16 Supplement 1

Abstracts of the 17th Annual SCMR Scientific Sessions

  • Poster presentation
  • Open Access

Refining risk assessment in cardiac sarcoidosis: a role for burden of late gadolinium enhancement and right ventricular function

  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
Journal of Cardiovascular Magnetic Resonance201416 (Suppl 1) :P302

https://doi.org/10.1186/1532-429X-16-S1-P302

©  Murtagh et al.; licensee BioMed Central Ltd. 2014

  • Published:

Keywords

  • Right Ventricular
  • Cardiovascular Magnetic Resonance
  • Sarcoidosis
  • Late Gadolinium Enhancement
  • Cardiac Sarcoidosis

Background

The presence of myocardial late gadolinium enhancement (LGE) in patients with sarcoidosis is a powerful predictor of major adverse events (MAE: death, ventricular tachycardia, or appropriate ICD therapy). In this study, we aim to determine if the burden of LGE, left ventricular (LV) and right ventricular (RV) end-diastolic and end-systolic volume index (EDVi & ESVi) and ejection fraction (EF) can be used to improve risk stratification in patients with cardiac sarcoidosis (CS).

Methods

We identified 25 consecutive subjects with a diagnosis of CS (biopsy-proven extra-cardiac sarcoidosis and presence of LGE on cardiovascular magnetic resonance). Imaging was performed on a 1.5T scanner. Short axis cines (6 mm thickness, 4 mm gap, temporal resolution < 40 ms) spanning the entire LV were acquired to determine LV and RV volumes. Short axis slices were also obtained 10 minutes after contrast (gadodiamide 0.15 mmol/kg) using a phase sensitive inversion recovery reconstruction. LGE was identified on each slice as regions with signal intensity (SI) > 5 standard deviations above the mean SI of normal remote myocardium. The total amount of LGE as a percentage of LV mass (%LGE) was determined using Diagnosoft Virtue software (Figure 1). Medical records were reviewed to identify MAE. Area under the curve (AUC) was determined from receiver-operator characteristics demonstrating the ability of %LGE, LVEDVi, LVESVi, LVEF, RVEDVi, RVESVi, and RVEF to detect MAE. Patients were divided into 2 groups; with MAE and without MAE. Each parameter was evaluated using unpaired T-tests. Continuous variables are presented as mean ± standard deviation.
Figure 1
Figure 1

Diagnosoft Virtue software was used to delineate areas of LGE (defined here as having a signal intensity > 5 standard deviations above that of normal remote myocardium).

Results

The mean age was 58 ± 7 years, 18 (72%) were female. Mean follow up was 39 ± 15 months. Six (24%) of patients had MAE. There was a significant difference in %LGE, RVEF and RVESVi but not LVEF, LVESVi, LVEDVi or RVEDVi between those who had MAE and those who did not (Table 1). The AUC for each of the following parameter's ability to predict MAE was: LVEF 0.54, LVEDVi 0.58, LVESVi 0.62, LGE 0.67, RVEDVi 0.76, RVESVi 0.85, and RVEF 0.56. Notably, in terms of predicting death, the AUC for %LGE, RVEDVi and RVESVi were high at 0.87, 0.86 and 0.89 respectively, while that for LVEF was 0.61, RVEF 0.61, LVEDVi 0.54 and LVESVi 0.55.
Table 1

Functional and structural parameters for subjects with and without major adverse events

 

MAE +

MAE -

P value

LVEF (%)

59 ± 4

60 ± 4

0.53

LVEDVi (ml/m2)

65 ± 22

27 ± 9

0.53

LVESVi (ml/m2)

27 ± 9

28 ± 7

0.72

RVEF (%)

42 ± 12

54 ± 9

0.01

RVEDVi (ml/m2)

86 ± 22

72 ± 14

0.09

RVESVi (ml/m2)

54 ± 18

34 ± 14

0.007

LGE (%)

20 ± 20

7 ± 5

0.01

Conclusions

The burden of LGE and RV size and function (not LV size and function) further improve prediction of death and significant ventricular arrhythmia in patients with cardiac sarcoidosis

Funding

None.

Authors’ Affiliations

(1)
University of Chicago, Chicago, Illinois, USA

Copyright

© Murtagh et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement

Journal of Cardiovascular Magnetic Resonance

ISSN: 1532-429X

Contact us